Carvedilol+VSL#3

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

Carvedilol+VSL#3 is one of 28 small molecule programs targeting Prophylaxis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProphylaxisCompleted

ProphylaxisPreclinical

Completed

Competition

Competitive Landscape

27 competitors in Prophylaxis

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Approved

13 2

Eliquis

Bristol-Myers Squibb

Approved

2 3

Bayer Aspirin

Bayer

Approved

2 4

Cymbalta

Jazz Pharmaceuticals

Approved

1 5

Coreg

Akero Therapeutics

Approved

4 6

Xarelto

WWim Janssens

Approved

4 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 8

Cabenuva

GSK

Phase 3

2 9

Lovenox

Sanofi

Phase 3

1 10

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prophylaxis1 trial

Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01196481·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carvedilol+VSL#3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carvedilol+VSL#3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carvedilol+VSL#3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Carvedilol+VSL#3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prophylaxis1 trial

References

Drug Info

Quick Facts

Related News